Inventor
OGURO YUYA
JP19 patents
⚠️ This page may combine multiple inventors who share the name “OGURO YUYA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TAKEDA PHARMACEUTICALS CO
13 patentsUS10323026B2Jun 18, 2019
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO20 citations85
US10610520B2Apr 7, 2020
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO9 citations83
US10807987B2Oct 20, 2020
Heterocyclic compound and use thereof
TAKEDA PHARMACEUTICALS CO5 citations72
US11230541B2Jan 25, 2022
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO2 citations71
US11827601B2Nov 28, 2023
Heterocyclic NMDA antagonists
TAKEDA PHARMACEUTICALS CO0 citations62
US11713311B2Aug 1, 2023
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO1 citations61
US11702419B2Jul 18, 2023
Heterocyclic compound and use thereof
TAKEDA PHARMACEUTICALS CO1 citations61
US11834409B2Dec 5, 2023
Heterocyclic NMDA antagonists
TAKEDA PHARMACEUTICALS CO0 citations60
US11746109B2Sep 5, 2023
Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate
TAKEDA PHARMACEUTICALS CO0 citations55
US12590086B2Mar 31, 2026
3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression
TAKEDA PHARMACEUTICALS CO0 citations50
US11952344B2Apr 9, 2024
Heterocyclic compound and use thereof
TAKEDA PHARMACEUTICALS CO0 citations50
US10131653B2Nov 20, 2018
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO0 citations50
US9655900B2May 23, 2017
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO0 citations50